Inovio Pharmaceuticals (NASDAQ:INO) Stock Passes Above 200 Day Moving Average - Should You Sell?

Key Points

• Inovio Pharmaceuticals' stock recently surpassed its 200-day moving average of $1.87, trading as high as $2.42, and currently sits at $2.28 with a trading volume of over 1.6 million shares.
• Analysts show mixed sentiments with Wall Street Zen downgrading the stock from "hold" to "sell," while Piper Sandler initiated coverage with an "overweight" rating and a price target of $5.00.
• Institutional investments are increasing, with significant increases in holdings by firms like Bank of America and Deutsche Bank, indicating potential long-term interest in Inovio Pharmaceuticals.

Inovio Pharmaceuticals, Inc. (NASDAQ:INO - Get Free Report) passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.87 and traded as high as $2.42. Inovio Pharmaceuticals shares last traded at $2.28, with a volume of 1,626,514 shares trading hands.

Analyst Ratings Changes

Several equities research analysts have commented on INO shares. Wall Street Zen cut Inovio Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Saturday, August 16th. Piper Sandler started coverage on Inovio Pharmaceuticals in a research report on Wednesday, July 9th. They set an "overweight" rating and a $5.00 price target on the stock. HC Wainwright reaffirmed a "neutral" rating and set a $3.00 price target on shares of Inovio Pharmaceuticals in a research report on Thursday, August 14th. Finally, Zacks Research lowered Inovio Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, September 3rd. Three analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, Inovio Pharmaceuticals has an average rating of "Moderate Buy" and a consensus target price of $8.80.

Inovio Pharmaceuticals Stock Performance

The stock has a market cap of $121.16 million, a price-to-earnings ratio of -0.87 and a beta of 1.61. The company has a 50-day simple moving average of $1.84 and a two-hundred day simple moving average of $1.87.

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) last posted its earnings results on Tuesday, August 12th. The biopharmaceutical company reported ($0.61) earnings per share for the quarter, topping analysts' consensus estimates of ($0.63) by $0.02. As a group, sell-side analysts predict that Inovio Pharmaceuticals, Inc. will post -4.23 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in INO. Northern Trust Corp increased its holdings in shares of Inovio Pharmaceuticals by 6.4% during the 4th quarter. Northern Trust Corp now owns 219,057 shares of the biopharmaceutical company's stock worth $401,000 after acquiring an additional 13,269 shares during the last quarter. Jane Street Group LLC increased its holdings in shares of Inovio Pharmaceuticals by 118.2% during the 4th quarter. Jane Street Group LLC now owns 39,704 shares of the biopharmaceutical company's stock worth $73,000 after acquiring an additional 21,512 shares during the last quarter. Bank of America Corp DE increased its holdings in shares of Inovio Pharmaceuticals by 1,035.2% during the 4th quarter. Bank of America Corp DE now owns 640,987 shares of the biopharmaceutical company's stock worth $1,173,000 after acquiring an additional 584,521 shares during the last quarter. Deutsche Bank AG increased its holdings in shares of Inovio Pharmaceuticals by 524.6% during the 4th quarter. Deutsche Bank AG now owns 89,864 shares of the biopharmaceutical company's stock worth $164,000 after acquiring an additional 75,477 shares during the last quarter. Finally, Graham Capital Management L.P. acquired a new position in shares of Inovio Pharmaceuticals during the 4th quarter worth approximately $114,000. 26.79% of the stock is owned by institutional investors and hedge funds.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.